Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder

Status: Open to Accrual 

Learn more: 

• https://clinicaltrials.gov/study/NCT06809140

Study contact: studies@hoosiercancer.org; (317) 921-2050.